Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety
| Autor: | Engy M. Aboelnaga, Wafaa El-Beshbishi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
safety medicine.medical_specialty business.industry capecitabine Low dose efficacy Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Metastatic breast cancer standard dose Capecitabine low dose Internal medicine medicine metastatic breast cancer business skin and connective tissue diseases RC254-282 medicine.drug |
| Zdroj: | Forum of Clinical Oncology, Vol 12, Iss 1, Pp 12-21 (2021) |
| Popis: | Background A lower dose of capecitabine revealed better toxicity profiles and comparable efficacy in treatment of metastatic breast cancer (MBC). We aimed to evaluate the efficacy and toxicity of lower dose of capecitabine in comparison with the standard dose. Patients and methods Patients were enrolled in two groups. Group 1 included 21 patients who received the standard dose of capecitabine (1250 mg/m2 twice daily [BID] for 14 days), while the patients in group 2 (19 patients) received lower dose of capecitabine (850 mg/m2 BID for 14 days) every 3 weeks. Results In group 1, dose reduction was reported in 12 (57.1%) patients versus 1 patient in group 2 (5.3%; P = 0.0005). Patients in group 1 reported higher toxicity rates without any significant difference between the groups. The median duration of response was 17 weeks in group 1, while it was 19 weeks in group 2. Disease progression was recorded in 10 (47.6%) patients in group 1 versus 8 (42.1%) patients in group 2 (P = 0.81). The mean time to progression was 8.16 ± 0.63 months and the median was 10.1 months in group 1, while the mean was 8.98 ± 0.75 months and the median was 10 months in group 2 (P = 0.66). The overall survival had a mean of 11.94 ± 0.754 and 11.24 ± 0.665 months, while the median was 13.1 and 13 months in groups 1 and 2, respectively (P = 0.9). Conclusions A lower dose of capecitabine provides MBC patients with an active therapy that can be continued for prolonged periods to achieve long-term disease control without compromising its antitumor activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|